Laboratory Characteristics in Chronic Atrophic Acrodermatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02147262|
Recruitment Status : Unknown
Verified May 2018 by Franc Strle, University Medical Centre Ljubljana.
Recruitment status was: Recruiting
First Posted : May 26, 2014
Last Update Posted : May 4, 2018
|Condition or disease||Intervention/treatment||Phase|
|Chronic Atrophic Acrodermatitis||Drug: doxycycline orally, 100 mg, bid, 14 days Drug: doxycycline orally, 100 mg, bid, 28 days||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Inflammatory Proteins,Gene Polymorphisms, and Transcriptome Profiles in Patients With Chronic Atrophic Acrodermatitis|
|Study Start Date :||July 2013|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||July 2020|
Active Comparator: ACA-doxy 14 days
patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days
Drug: doxycycline orally, 100 mg, bid, 14 days
Active Comparator: ACA-doxy 28 days
patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
Drug: doxycycline orally, 100 mg, bid, 28 days
- inflammatory proteins in patients with chronic atrophic dermatitis [ Time Frame: up to 24 months ]The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses.
- clinical characteristics of patients with chronic atrophic dermatitis treated with doxycycline for 14 or 28 days [ Time Frame: at enrollment, at 2, 6 12 and 24 months follow-up ]
- gene polymorphisms in patients with chronic atrophic dermatitis [ Time Frame: at enrollment, at 6 months follow-up ]The expression of disease-relevant genomic variants will be assessed using ImmunoChip.
- transcriptome profiles in patients with chronic atrophic dermatitis [ Time Frame: at enrollment ]We will use RNA sequencing of individual immune cell subtypes from patients to determine their transcriptome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02147262
|Contact: Dasa Stupica, MD, PhD||+386 1 522 email@example.com|
|Contact: Franc Strle, MD, PhD||+386 1 522 firstname.lastname@example.org|
|Study Chair:||Franc Strle, MD, PhD||UMC Ljubljana|
|Principal Investigator:||Dasa Stupica, MD, PhD||UMC Ljubljana|